Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a publication in the scientific journal, PLOS One, which demonstrates the superiority of Organovo’s 3D bioprinted human liver tissues to effectively model drug-induced liver injury and distinguish between highly-related compounds with different toxicity profiles.
Using Organovo’s 3D bioprinted human liver tissues, researchers from Organovo and Roche Pharmaceutical Research and Early Development (“Roche”) were able to detect significant dose-dependent toxicity of trovafloxacin at clinically relevant doses, compared to levofloxacin, a structurally related, but non-toxic compound. The hepatotoxic potential of trovafloxacin was not originally identified by traditional preclinical tests including animal studies. Trovafloxacin is a third-generation anti-infective drug that was withdrawn from the market one year following its approval due to liver failure and death in a small proportion of patients. Deborah G. Nguyen, Ph.D., Senior Director of Research & Development, was Organovo’s lead author for the publication.
“This publication clearly shows the outstanding performance of Organovo’s 3D bioprinted human liver tissues when compared to traditional preclinical tests in replicating human drug response at the tissue level,” said Dr. Sharon Presnell, chief scientific officer, Organovo.
Drug-induced liver injury is a major cause of late-stage clinical failures and post-market drug withdrawals. Existing preclinical tests include conventional 2D cell culture models, which lack longevity and cannot replicate the complex cell-cell interactions and environment of human tissue. Animal models can miss compounds that are toxic in humans because of species variations and other factors. Read more
Source: Organovo Press Release